Equine Serum for Therapy Market By Offering (Tetanus Toxoid (Tetanus Toxoid Concentrated, Tetanus Toxoid Unconcentrated, Tetanus Antitoxin), Anthrax Vaccine, Normal Serum (Equine Origin), West Nile Antibody, Clostridium Perfringens Types C&D Antitoxin, Others); By End Users (Livestock Owners, Veterinarians); By Distribution Channel (Direct, Indirect); By Region (Northeast, West, South, Midwest) – United States Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Equine serum is the serum harvested from controlled donor herds. The product is synthesized, and made available for applications such as anthrax vaccination, tetanus toxoid, antitoxin for Clostridium Perfringens types, amongst others. Studies from the Historical Medical Library of The College of Physicians of Philadelphia indicate that serum was drawn from horses as early as 1895, after they have been injected with various toxins. Antitoxins were then produced for a variety of diseases that include diphtheria, tetanus, and scarlet fever, amongst others. Advancements in medical treatment along with increased investments towards innovations in the field of animal vaccines, diagnostics and medications has led to longer life span of companion animals at large. However, rise in equine diseases is facilitating the growth of equine serum for therapy market. West Nile Virus (WNV) is among the most prominent causes of arbovirus encephalitis in humans and horses. Horses account for about 96.9% of all the non-human mammalian cases reported for WNV diseases. The fatality rates amongst horses which exhibit clinical signs of this disease is approximately 30%. Timely and consistent vaccination doses are recommended for horses, especially before the onset of insect vector season, so as to ensure protective immunity during the periods of likely exposure. For instance, several veterinarians in the Southern states of United States chose to vaccinate horses more frequently, since the mosquitoes are active throughout the year in this region. Hence, increasing precautionary measures adopted by veterinarians and livestock owners to prevent spread of fatal diseases showcases positive growth prospects for United States equine serum for therapy market over the forecast period.
In terms of revenue, United States equine serum for therapy market was valued at US$ 14,818 Thousands in 2020 growing at a CAGR of 3.2% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
United States Equine Serum for Therapy Market Revenue & Forecast, (US$ Million), 2015 – 2029
Offering Outlook:
On the basis of offering, United States equine serum for therapy market is classified on the basis of tetanus toxoid, anthrax vaccine, normal serum (equine origin), West Nile Antibody, clostridium perfringens types C&D antitoxin and others. Tetanus toxoid, which is further categorised into tetanus toxoid concentrated, tetanus toxoid unconcentrated, tetanus antitoxin, accounted for the highest share in 2020. Tetanus toxoid is regarded as a core vaccine and is also recommended by the American Association of Equine Practitioners (AAEP) for every equine. The dosage is given annually to the equines and is administered as an intramuscular injection. The vaccines for West Nile and Encephalitis are commonly combined with tetanus toxoid in the same dosage.
End Users Outlook:
Based on end users, the United States equine serum for therapy market is bifurcated into livestock owners and veterinarians. Veterinarians’ end users accounted for a substantial share in the market in 2020. Depending upon the adverse reaction of the therapeutic, specific categories of medication are explicitly advised to be used only by the veterinarians. For instance, the dosage of 50ml to 250ml of Normal Serum, provided by Colorado Serum Company, is injected intramuscularly, subcutaneously, or intravenously depending upon the judgement of the veterinarian administering and weight of the animal. The serum, which is intended for non-specific treatment of equine disease conditions and infections, is specifically marked for veterinary use only.
Distribution Channel Outlook:
Distribution channel segment in the United States equine serum for therapy market is classified into direct and indirect. Direct distribution of equine serum for therapy has remained prevalent in the United States. The companies supplied the products using direct distribution channels to enhance the relations with the end-users. However, the growing investments towards diversification of distribution channels to increase the reach to a larger consumer base is fuelling the growth of indirect distribution channel
Region Outlook:
Geographically, United States equine serum for therapy market is classified into Northeast, West, South and Midwest. South region in the United States accounted for a major share in 2020. Regulatory conditions prevalent in the United States and other countries globally, has limited its distribution across limited countries. Northeast region in the United States equine serum for therapy market is however anticipated to register highest growth rate over the forecast period.
Competitive Landscape:
The report provides both, qualitative and quantitative research of United States equine serum for therapy market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their regional presence, competitors, service offerings and specification amongst others.
Some of the players operating in the United States equine serum for therapy market are Colorado Serum Company, MG Biologics, and Boehringer Ingelheim amongst other industry participants.
United States Equine Serum for Therapy Market:
By Offering:
- Tetanus Toxoid
- Tetanus Toxoid Concentrated
- Tetanus Toxoid Unconcentrated
- Tetanus Antitoxin
- Anthrax Vaccine
- Normal Serum (Equine Origin)
- West Nile Antibody
- Clostridium Perfringens Types C&D Antitoxin
- Others
By End Users:
- Livestock Owners
- Veterinarians
By Distribution Channel:
- Direct
- Indirect
By Region:
- Northeast
- West
- South
- Midwest
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. United States Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Equine Serum for Therapy Market
6. Market Synopsis:
Equine Serum for Therapy Market
7. Equine Serum for Therapy Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Equine Serum for Therapy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Equine Serum for
Therapy Market
7.6. Porter’s Five Force Analysis
8. United States Equine Serum for Therapy Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. United States Equine Serum for Therapy Market Revenue (US$ Mn)
8.2. United States Equine Serum for Therapy Market Revenue (US$ Mn)
and Forecasts, By Offering
8.2.1. Tetanus Toxoid (Definition, Market Penetration (2019), Market
Estimation (2015 - 2020), Market Forecast (2021 - 2029), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (Northeast, West, South, Midwest) and
Information on Tetanus Toxoid Concentrated, Tetanus Toxoid Unconcentrated,
Tetanus Antitoxin)
8.2.1.1. Tetanus Toxoid Concentrated
8.2.1.2. Tetanus Toxoid Unconcentrated
8.2.1.3. Tetanus Antitoxin
8.2.2. Anthrax Vaccine
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. Northeast
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. West
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. South
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Midwest
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.3. Normal Serum (Equine Origin)
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. Northeast
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. West
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. South
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Midwest
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.4. West Nile Antibody
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. Northeast
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 - 2029
8.2.4.5.2. West
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 - 2029
8.2.4.5.3. South
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 - 2029
8.2.4.5.4. Midwest
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 - 2029
8.2.5. Clostridium Perfringens Types C&D Antitoxin
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2020
8.2.5.3. Market Forecast, 2021 - 2029
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. Northeast
8.2.5.5.1.1. Market
Estimation, 2015 - 2020
8.2.5.5.1.2. Market
Forecast, 2021 - 2029
8.2.5.5.2. West
8.2.5.5.2.1. Market
Estimation, 2015 - 2020
8.2.5.5.2.2. Market
Forecast, 2021 - 2029
8.2.5.5.3. South
8.2.5.5.3.1. Market
Estimation, 2015 - 2020
8.2.5.5.3.2. Market
Forecast, 2021 - 2029
8.2.5.5.4. Midwest
8.2.5.5.4.1. Market
Estimation, 2015 - 2020
8.2.5.5.4.2. Market
Forecast, 2021 - 2029
8.2.6. Others
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 - 2020
8.2.6.3. Market Forecast, 2021 - 2029
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. Northeast
8.2.6.5.1.1. Market
Estimation, 2015 - 2020
8.2.6.5.1.2. Market
Forecast, 2021 - 2029
8.2.6.5.2. West
8.2.6.5.2.1. Market
Estimation, 2015 - 2020
8.2.6.5.2.2. Market
Forecast, 2021 - 2029
8.2.6.5.3. South
8.2.6.5.3.1. Market
Estimation, 2015 - 2020
8.2.6.5.3.2. Market
Forecast, 2021 - 2029
8.2.6.5.4. Midwest
8.2.6.5.4.1. Market
Estimation, 2015 - 2020
8.2.6.5.4.2. Market
Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Offering
9. United States Equine Serum for Therapy Market Analysis and
Forecasts, 2021 – 2029
9.1. Overview
9.2. United States Equine Serum for Therapy Market Revenue (US$ Mn)
and Forecasts, By End Users
9.2.1. Livestock Owners
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. Northeast
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. West
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. South
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Midwest
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.2. Veterinarians
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. Northeast
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. West
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. South
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Midwest
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By End Users
10. United States Equine Serum for Therapy Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. United States Equine Serum for Therapy Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
10.2.1. Direct
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. Northeast
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. West
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. South
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Midwest
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.2. Indirect
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. Northeast
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. West
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. South
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Midwest
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Distribution Channel
11. United States Equine Serum for Therapy Market Analysis and
Forecasts, 2021 – 2029
11.1. Overview
11.2. United States Equine Serum for Therapy Market Revenue (US$ Mn)
and Forecasts, By Region
11.2.1. Northeast
11.2.1.1. Northeast Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Offering
11.2.1.1.1. Tetanus Toxoid
11.2.1.1.1.1. Tetanus
Toxoid Concentrated
11.2.1.1.1.2. Tetanus
Toxoid Unconcentrated
11.2.1.1.1.3. Tetanus
Antitoxin
11.2.1.1.2. Anthrax Vaccine
11.2.1.1.3. Normal Serum (Equine Origin)
11.2.1.1.4. West Nile Antibody
11.2.1.1.5. Clostridium Perfringens Types C&D Antitoxin
11.2.1.1.6. Others
11.2.1.2. Northeast Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By End Users
11.2.1.2.1. Livestock Owners
11.2.1.2.2. Veterinarians
11.2.1.3. Northeast Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.2.1.3.1. Direct
11.2.1.3.2. Indirect
11.2.2. West
11.2.2.1. West Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Offering
11.2.2.1.1. Tetanus Toxoid
11.2.2.1.1.1. Tetanus
Toxoid Concentrated
11.2.2.1.1.2. Tetanus
Toxoid Unconcentrated
11.2.2.1.1.3. Tetanus
Antitoxin
11.2.2.1.2. Anthrax Vaccine
11.2.2.1.3. Normal Serum (Equine Origin)
11.2.2.1.4. West Nile Antibody
11.2.2.1.5. Clostridium Perfringens Types C&D Antitoxin
11.2.2.1.6. Others
11.2.2.2. West Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By End Users
11.2.2.2.1. Livestock Owners
11.2.2.2.2. Veterinarians
11.2.2.3. West Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.2.2.3.1. Direct
11.2.2.3.2. Indirect
11.2.3. South
11.2.3.1. South Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Offering
11.2.3.1.1. Tetanus Toxoid
11.2.3.1.1.1. Tetanus
Toxoid Concentrated
11.2.3.1.1.2. Tetanus
Toxoid Unconcentrated
11.2.3.1.1.3. Tetanus
Antitoxin
11.2.3.1.2. Anthrax Vaccine
11.2.3.1.3. Normal Serum (Equine Origin)
11.2.3.1.4. West Nile Antibody
11.2.3.1.5. Clostridium Perfringens Types C&D Antitoxin
11.2.3.1.6. Others
11.2.3.2. South Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By End Users
11.2.3.2.1. Livestock Owners
11.2.3.2.2. Veterinarians
11.2.3.3. South Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.2.3.3.1. Direct
11.2.3.3.2. Indirect
11.2.4. Midwest
11.2.4.1. Midwest Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Offering
11.2.4.1.1. Tetanus Toxoid
11.2.4.1.1.1. Tetanus
Toxoid Concentrated
11.2.4.1.1.2. Tetanus
Toxoid Unconcentrated
11.2.4.1.1.3. Tetanus
Antitoxin
11.2.4.1.2. Anthrax Vaccine
11.2.4.1.3. Normal Serum (Equine Origin)
11.2.4.1.4. West Nile Antibody
11.2.4.1.5. Clostridium Perfringens Types C&D Antitoxin
11.2.4.1.6. Others
11.2.4.2. Midwest Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By End Users
11.2.4.2.1. Livestock Owners
11.2.4.2.2. Veterinarians
11.2.4.3. Midwest Equine Serum for Therapy Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
11.2.4.3.1. Direct
11.2.4.3.2. Indirect
12. Competitive Benchmarking
12.1. Market Share Analysis, 2020
12.2. United States Presence and Growth Strategies
12.2.1. Mergers and Acquisitions
12.2.2. Product Launches
12.2.3. Investments Trends
12.2.4. R&D Initiatives
13. Player Profiles
13.1. Colorado Serum Company
13.1.1. Company Details
13.1.2. Company Overview
13.1.3. Product Offerings
13.1.4. Key Developments
13.1.5. Financial Analysis
13.1.6. SWOT Analysis
13.1.7. Business Strategies
13.2. MG Biologics
13.2.1. Company Details
13.2.2. Company Overview
13.2.3. Product Offerings
13.2.4. Key Developments
13.2.5. Financial Analysis
13.2.6. SWOT Analysis
13.2.7. Business Strategies
13.3. Boehringer Ingelheim
13.3.1. Company Details
13.3.2. Company Overview
13.3.3. Product Offerings
13.3.4. Key Developments
13.3.5. Financial Analysis
13.3.6. SWOT Analysis
13.3.7. Business Strategies
13.4. Other Market Participants
Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.